A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.

 
Web www.patentalert.com

< HCV core protein binding agents for treatment of hepatitis C virus infection

< Extracorporeal pathogen reduction system

> Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

> Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use

~ 00278